Drug intelligence / Profile preview

TQB2868

Development stage: Phase 3
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TQB2868 is a bifunctional fusion protein under clinical development for the treatment of advanced malignant tumors, including hepatocellular carcinoma and metastatic pancreatic cancer. It targets both programmed cell death protein 1 (PD-1) and transforming growth factor beta (TGF-beta), acting as an immune checkpoint inhibitor and a neutralizer of immunosuppressive signals in the tumor microenvironment. By blocking PD-1-mediated signaling and neutralizing TGF-beta, TQB2868 aims to restore cytotoxic lymphocyte activity, enhance immune response against tumors, inhibit tumor proliferation, and overcome resistance mechanisms associated with immunosuppression[1][2][4][5].

Other names: anti-PD-1/anti-TGF-beta bifunctional fusion protein TQB2868anti-PD-1/TGF-beta bifunctional fusion protein TQB2868

Targets

TGFB (GARP–latent transforming growth factor beta 1 complex)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on TQB2868.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB2868.

Explore the full profile